Clinical Data Summary: Multi-dose Study
Effective oral delivery with an EMISPHEREŽ carrier in a 10-day multiple dose safety study in allergic subjects
Rapid absorption of oral cromolyn (tmax ɘ.5h)
Cromolyn plasma concentration significantly higher than those seen with pulmonary delivery
Impact on allergic response in some subjects
Well tolerated; no adverse events reported